Abstract
To the Editor.—
I have just completed reading the article published in Pediatrics on the live, attenuated varicella vaccine (Varivax), written by the groups from Merck Sharp & Dohme and Biogen Incorporated.1 I was quite impressed with their clinical data concerning the relatively small number of acute side effects and the apparent immunogenicity of the vaccine. Although I'm sure that more studies are in progress, on the basis of the above data, one would think that United States licensure should be right around the corner.
- Copyright © 1992 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.